THE ANTICOAGULANT AND ANTILYMPHOMA PROPERTIES OF ARSENIC AZOPROTEINS : II. COMBINATION OF ARSENIC AZOPROTEINS WITH FIBRINOGEN AND POLYMERIZING FIBRIN IN VITRO: ALTERATIONS IN MITOSIS OF LYMPHOMA 6C3HED CELLS INDUCED IN VIVO WITH ARSENIC AZOPROTEINS: DISCUSSION OF MEANS WHEREBY ARSENIC AZOPROTEINS MAY ACT UPON LYMPHOMA 6C3HED CELLS IN VIVO by Broome, J. D. & Kidd, John G.
THE  ANTICOAGULANT AND  ANTILYMPHOMA  PROPERTIES 
OF  ARSENIC  AZOPROTEINS* 
II.  COMBINATION OF  ARSENIC AZOPROTEINS WITH FIBRINOGEN AND POLY- 
MERIZING FIBRIN  IN VITRO: ALTERATIONS IN MITOSIS  OF  LYMPHOMA 
6C3HED  CELLS INDUCED IN VIVO WITH ARSENIC AZOPROTEINS: 
DISCUSSION OF  MEANS  WHEREBY ARSENIC AZOPROTEINS 
MAY AcT UPON LYMP~rOI~A 6C3HED  CELLS IN VIVO 
BY J.  D. BROOME,~ M.B.,  AND JOHN  O. KIDD, M.D. 
(From the Department of Pagkology, The New York ttospital--CorneU Medical 
Center, New York) 
(Received for publication, May 14, 1964) 
In extension of findings given in the previous paper,  we have now observed 
that  4-arsonophenylazoproteins  combine  avidly with  fibrinogen  in  ~itro, the 
complex being resistant to the enzymic action of  thrombin. Also, that arsenic 
azoproteins  react  strongly  with  polymerizing fibrin,  the  reaction  producing 
effects of an unusual kind on the final stages of the clotting process and having 
other  implications  besides.  And  further,  that  4-arsonophenylazoproteins  act 
powerfully on proliferating Lymphoma 6C3HED  cells in viro  to inhibit chro- 
mosome separation in metaphase, a process known to be dependent on the for- 
marion and contraction of the  mitotic spindle through polymerization of pro- 
teins (22-25). 
The findings mentioned above will now be given in detail,  and the possibility 
will be considered that 4-arsonophenylazoproteins may exert their anticaogulant 
and antilymphoma effects in similar and perhaps related ways. 
Materials and Metkods 
The preparation  of the azoproteins and related substances has been described in the pre- 
ceding paper. 
Fibrinogen preparations were of three kinds, as indicated in the text. For some experiments 
bovine fibrinogen (Armour Pharmaceutical Company, Kankakee, Illinois, Cohn's fraction I) 
was used. In other experiments this preparation was purified according to the method of I.aki 
(1). In yet other experiments a preparation of bovine fibrinogen obtained from Pentex Inc., 
Kankakee, Illinois, and containing 90 per cent thrombin-coagulable  protein was used. Throm- 
bin used was topical preparation of Parke Davis and Company, Detroit. 
* This study was supported by grants from Mr. John W. O'Boyle, the National  Cancer 
Institute, and the American Cancer Society. 
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Arsanilic acid (reagent grade) for injection into mice was dissolved in the minimum quantity 
of 0. I N NaOH, the pH of the solution adjusted to 7.0 and the solution was Seitz filtered. 
Colchicine u.s.P, was dissolved in water and Seitz filtered, each day immediately before use. 
RESULTS 
Effects of Azoproteins on the Clotting of Fibrinogen by  Thrombin.--When 4- 
arsono-,  4-sulfono- and 4-carboxyphenylazoproteins were added to mixtures of 
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FIGs. i  and 2. The effect of increasing concentrations of thrombin on the rate of dotting of 
solutions containing fixed concentrations of azoproteins and fibrinogen. 4-Sulfonophenylazo- 
albumin preparation I, contained 1.7 per cent sulfur in sulfonic groups and preparation 2, 3.4 
per cent. Clotting mixtures: 0.4 ml bovine fibrinogen solution (Pentex, Inc., 200 mg per cent in 
0.154 ~  NaCi-0.01 ~  phosphate pH 7.1)  containing azoproteins (AP) designated at concen- 
tration of 0.15 mg/ml. 0.I ml thrombin. 
human plasma and thrombin, the dotting process was markedly inhibited. In- 
hibition occurred,  too, when fibrinogen  alone was used, and indeed here the 
pattern of inhibition showed particular quantitative relationships.  Figs.  I and 
2 show that, in different experiments, the speed of clotting in systems contain- 
ing these azoproteins bears a constant relationship to that in the controls using 
thrombin concentrations from 1.0 to 10.0 units/ml. In other experiments (Figs. 
3 and 4) the delay in dotting time was directly proportional to the concentra- 
tion of azoprotein, above the lowest concentrations (0.025 mg/ml or less).  The 
kinetic  relationships  are  typical  of  those  produced  by reversible  inhibitors 
of enzymic reactions (2), but on account of the complexity and  the  number 
of  different  reactions  involved  in  the  clotting  of  fibrinogen,  as  will  be J. D. BR00ME AND JOHN G. KIDD  469 
described,  they do not provide decisive information on the exact inhibitory 
mechanism. These experiments  however immediately made  one point  clear, 
namely that the mechanism of inhibition differs greatly from that caused by 
heparin. For with the purified fibrinogen used in these experiments, heparin, 
which requires a  plasma cofactor for its activity (3),  was almost completely 
devoid of effect, even at a concentration (0.1 mg/ml) which produces complete 
incoagulability of plasma. 
When other analogues of 4-arsonophenylazoproteins were  tested for their 
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FIGS. 3 and 4. The effect  of increasing  concentrations  of azoproteins on the delsy in clot- 
ring of solutions  containing  fixed amounts  of fibrinogen  and thrombin. Clotting mixtures:  0.6 
ml bovine fibrinogen  solution (Pentex, Inc., 300 mg per cent in 0.15 ~r NaC1-0.01 ~ phosphate 
pH 7.0). 0.1 ml thrombin (10 units/ml). AP, azoproteins. 
effects on the clotting of fibrinogen by thrombin, they produced results similar 
to those obtained with recalcified plasma. Anticoagulant activity was confined 
to the acidic azoproteins (Table I). Again the anticoagulant activity of 4-arson- 
ophenylazoalbumins increased with their arsenic content, up to approximately 
6.5  per cent (Table II), while in other experiments substances containing 11 
and 17 per cent As were markedly less effective. Azoalbumins were more active 
than azoglobulins of comparable arsenic content, but the 4-arsonophenylazo 
derivatives of amino acids and of polypeptides had no anticoagulant activity. 
Similarly two  4-arsonophenyl derivatives  of bovine  albumin  which did not 
contain azo linkages were ineffective. 
The Mechanism  of Inhibition  of the Throrabin-Induced Clotting of Fibrinogen 
by Acidic Azoproteins.--In recent years the final stages in the clotting process 
have been studied by a number of workers (see reviews of Scheraga and Laskow- 
ski, reference 4, and B16mback, reference 5). It has been found that the appear- 470  ARSENIC  AZOPROTEINS.  II 
ance  of a  clot in mixtures  of fibrinogen  and  thrombin  is  preceded  by three 
distinct stages. In the first, thombin acts enzymicaUy on fibrinogen to liberate 
2 distinct peptides and carbohydrate substances of less well defined composition, 
converting the fibrinogen molecule into a monomer of fibrin. In the second stage 
monomers condense to form short polymers of varying size. In the third stage, 
TABLE I 
The Effect of Azoproteins  on the ThromMn-Induced Clotgng Time of Fibrinogen 
Clotting mixture: 0.3 ml fibrinogen solution (200 mg per cent)  +  0.02 ml of the protein 
solutions (each 5 gm per cent). 
Protein solutions 
Control, bovine albumin 
Azoproteins 
4-Sul  fonophenylazoalbumiu  (Bovine) 
~  cc 
4-Arsonophenylazoalbumin  " 
c~  c¢ 
"  (Human) 
4-Ar  sonophenylazoglobulin  " 
4-Carboxyphenylazoalbumin  (Bovine) 
4-Aminophenylazoalbumin  " 
Phenylazoalbumin  " 
Mixtures of bovine albumin, and 
Sulfanilic acid (1 gm per cent) 
Arsanilic acid (1 gm per cent) 
p-Aminobenzoic acid (1 gm per cent) 
S  content  (from 
sulfonic  groups)  or 
As content 
~er cent 
S  content 
1.7 
3.4 
As content 
1.8 
4.0 
d.5 
7.5 
Clotting time 
after addition 
of 0.1 ml 
thrombin 
(3 units ml) 
mlu.  sec, 
18 
2  18 
cc 
54 
3  27 
7 
3  5 
6 
19 
18 
18 
18 
19 
Solutions made in 0.15 ~ NaC1 and pH adjusted  to 7.0 with 0.15 ,~ NaOh. 
the  intermediate  polymers  combine  in  a  highly  organized  manner  to  form 
strands of insoluble fibrin. 
Theoretically, the acidic azoproteins might inhibit the clotting of fibrinogen- 
thrombin mixtures by acting on any of the three  stages which have been de- 
scribed. 
Acidic azoproteins produced no demonstrable destruction of thrombin itself 
(see Figs.  1 to 4), Prior incubation of azoprotein with thrombin  (for example, 
in one experiment incubating 1 ml of a solution containing 0.5 mg of 4-arsono- 
phenylazoprotein  and  10  units  thrombin  at  37°C  for  30  minutes)  failed  to J,  D.  BROOME  AND  JOt~l"  G.  KIDD  471 
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cause any greater anticoagulant effect than when azoprotein came in contact 
with thromin only at the beginning of the clotting process. Similarly, virtually 
no inhibitory effect was produced on the hydrolytic action of thrombin on tosyl 
arginine methyl ester (6). For example, in incubation mixtures, hydrolysis pro- 
duced by 5 units/rnl of thrombin on 0.01 ~s tosyl arginine methyl ester solution 
proceeded at 86 to 99 per cent of the control rate in the presence of concentra- 
tions of 4-arsono-, 4-sulfono-, and 4-carboxyphenylazoalbumin of 8.0 mg/ml. 
TABLE  III 
The Ability of Acidic Proteins to Form Precipitates from Acidified Plasma 
Incubation  mixtures: 0.4 ml human  plasma  (citrated-diluted  1:3 in 0.15 ~  NaC1 and 
acidified by addition of 0.15 N HC1). 0.003 ml azoprotein solutions (10 gm per cent in 0.15 
NaC1). 
Azoprotein  used 
None 
4-Arsonophenylazo- 
albumin  (prepara- 
tion M9) 
4-Sulfonophenylazo- 
albumin  (prepara- 
tion SABA2) 
4-Carboxyphenylazo- 
albumin  (prepara- 
tion PAB3) 
Degree of precipitate formation*  at the following pH values: 
7.0  6.7  6.5 
a:  + 
6,3  6.1  5,9 
+  ++ 
++  +++  +++ 
+  +  ++ 
5.6 
+++ 
+++ 
+++ 
5.4 
+++ 
+++ 
+++ 
5.2 
-4- 
+++ 
++ 
+++ 
5.0 
4- 
+ 
+ 
++ 
:h,  slight opalescence; +, marked opalescence; ++,  fine, granular precipitate;  +++, 
heavy, flocculent precipitate. 
* Observations made 5 minutes after addition of azoprotein to plasma samples incubated 
at 37°C. 
In comparable experiments these concentrations of azoprotein caused complete 
inhibition of the clotting of fibrinogen. Further experiments soon showed that 
the inhibitory action of acidic azoproteins was brought about by reaction with 
the fibrinogen itself. 
Reaction of Acidic Azoproteins  with Fibrinogen.--It  was observed that when 
4-arsonophenylazoprotein  was  added  to  slightly  acidified  human  plasma,  a 
colored precipitate formed. No  such  change  occurred when  serum was used. 
When the phenomenon was examined in further detail (Table III) it was seen 
that 4-arsonophenylazoalbumin and also 4-carboxyphenylazoalbumin brought 
about the formation of a precipitate when mixed with plasma at pH 6.1.4-Sul- 
ionophenylazoprotein caused precipitation at even higher pH, a  distinct  tur- 
bidity was  observed at  pH  6.7,  and  the  quantity  of precipitate  reached  its J.  D.  BROOM]B AND  JOHN  O.  KIDD  473 
maximum at pH 6.3. In each case, the precipitate redissolved on restoring the 
pH to neutrality. With stronger acidification,  to pH values of 5.2 and below, 
plasma alone became turbid, but at these pH values scarcely any change was 
produced on the addition of azoprotein. 
In keeping with their lack of anticoagulant properties, azoproteins without 
an acidic  group  caused no precipitation,  and  neither  did 4-arsonophenylazo 
derivatives of peptones or amino acids.  In other experiments 4-arsonophenyl- 
carbamoylmethylalbumins  and  4-arsonophenyltriazinylalbumins,  substances 
which lacked an azo group, failed to cause precipitation despite their content of 
arsonic  groups. 
Numerous experiments showed that the precipitate formed from plasma was 
in fact a complex of azoprotein and fibrinogen, for (a) serum showed no precipi- 
tation in the presence of the acidic azoproteins under identical conditions  to 
those shown with plasma,  till pH values below 5.2 were reached;  (b) plasma, 
from which fibrinogen was removed by ~  saturation with sodium chloride or 1/~ 
saturation with ammonium sulfate, followed by dialysis against 0.15 M sodium 
chloride,  failed to produce any precipitate on the addition of azoprotein at pH 
values above 5.2, whereas the fibrinogen-containing  fraction similarly  treated 
was immediately precipitated by azoprotein at pH 6.3; and (c) when the pre- 
cipitate formed from the mixture of acidified plasma and azoprotein was sepa- 
rated and dissolved in 0.15 M NaCI at pH 7.0, high concentrations of thrombin 
(i50 units/ml) brought about coagulation,  although, instead of the usual gelat- 
inous clot a lumpy precipitate was slowly formed. 
Highly purified preparations of fibrinogen  readily formed a precipitate with 
acidic azoproteins, and indeed at a higher pH than was observed with plasma. 
For example, a preparation of bovine fibrinogen, (protein 90 per cent coagulable 
by thrombin) was dissolved (1.5 mg/ml) in 0.14 ~ NaC1-0.01  ~r sodium phos- 
phate buffer at pH 7.7. When either 4-arsono-,  4-sulfono-, or 4-carboxyphenyl- 
azoalbumins were added at concentrations of 0.1 mg/ml, cloudiness  which led 
to heavy precipitation  developed after 2 hours at room temperature.  In the 
absence of azoproteins the fibrinogen  showed no instability under these condi- 
tions. A similarly delayed precipitation occurred at pH 7.2, but below this, at 
pH 6.5 a heavy precipitation immediately formed. 
It is clear from these experiments that acidic azoproteins form particularly 
strong  complexes with fibrinogen.  The formation of insoluble  azoprotein-pro- 
tein complexes in the interisoelectric  regions, that is, at pH values between the 
isoelectric points of the azoprotein and  the protein under test has been shown 
previously by Horowitz et al.  (7). But as the isoelectric  point of fibrinogen  is 
pH 5.5 (8) and that of the acidic azoalbumins less than  4.4 (9, 10) the complex 
formation now demonstrated plainly occurs under quite different  conditions. 
Indeed considerably less precipitation occurs in the interisoelectric  region than 
at higher pH values. 474  ARSENIC  AZOPROTEINS.  II 
These results then showed that the inhibitory action of azoproteins on the 
thrombin induced clotting process could be explained by the formation of an 
azoprotein-fibrinogen complex, producing a substrate resistant to the enzymic 
action of thrombin. Confirmatory evidence for this explanation was obtained by 
measuring the anticoagulant effectiveness of acidic phenylazoproteins at differ- 
ent pH values. 
Effects of Changes in pH on the Anticoagulant  E~rectivencss of Acidic Azopro- 
teins.--It has been shown that the binding of fibrinogen to acidic azoproteins 
becomes stronger at pH values decreasing from neutrality. If, therefore, the 
anticoagulant action is due to such a combination then it, too, should increase 
under similar conditions. The results shown in Table IV bear this out, for al- 
though a change in pH from 7.0 to 6.4 did not alter the clotting times induced 
by thrombin in control plasma samples, the anticoagulant effectiveness of the 
3 acidic azoproteins increased markedly. Conversely, increasing the pH from 
7.1 to 8.0, which again had no effect on the clotting time of controls, resulted in 
a marked decrease in anticoagulant activity. Comparable results were obtained 
using purified bovine fibrinogen and thrombin mixtures at different pH values. 
These results, however, did not exclude the possibility that acidic azoproteins 
might also act on the polymerization processes.  This possibility was examined 
directly. 
Effects of Azoproteins and Related Substances on the Pol3mwrization of Fibrin.- 
The experiments of Waugh and coworkers (11-13)  have shown that under con- 
ditions similar to those occurring in vivo the enzymic action of thrombin on 
fibrinogen is the rate limiting step in the clotting of fibrinogen. But under con- 
ditions of increased electrolyte concentration or decreased pH the polymeriza- 
tion reactions are markedly inhibited  and instead their rate now controls the 
speed of clot formation (1, 14). By using such systems the effect of azoproteins 
on fibrin polymerization may be examined directly, and independently of ac- 
tions on other stages. 
(a)  Effects  of azoproteins  and related substances  on systems  in which fibrin 
polymerization  is inhibited  at acid pH: The principle of the present experiment 
depends on the finding of Laki (1) that at pH 5.0 thrombin acts on fibrinogen 
at a slow rate to produce fibrin monomers, but under such conditions these are 
unable to polymerize and therefore accumulate. When the pH is raised to 7.0 
two changes take place, thrombin begins to act more rapidly, and the accumu- 
lated fibrin monomers begin to polymerize. Clot formation results. The speed 
of clotting plainly depends  on both processes,  but will be  more  rapid with 
increasing initial concentration of fibrin monomers. When the initial concentra- 
tion of fibrin monomers is sufficiently  high the speed of clot formation following 
the restoration of the pH to neutrality will then come close to being a measure- 
ment of polymerization rate. 
The results of an experiment performed in this way are shown in Table V. ~. D. BROOKE  AND  ~OHN  G. KIDD  475 
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4-Arsonophenylazoalbumin, in marked contrast to the inhibitory effects shown 
on other clotting processes, here produced a marked acceleration of clotting in 
systems containing monomeric fibrin. The accelerating effect became particu- 
larly  marked  in  preparations  in which  fibrinogen-thrombin  incubation  was 
prolonged for  16 hours  at  acid pH. Mter  the pH was raised  to  6.8,  control 
mixtures  clotted  in  48  seconds,  while  in  the  presence  of 4-arsonophenylazo- 
albumin this time was reduced to  10 seconds. 
Polymerization of fibrin was also accelerated by 4-sulfono- and 4-carboxy- 
TABLE V 
The Acceleration of Fibrin Polymerization by 4-Arsonophenylasoprotein 
Incubation  mixture (pH 5.1): 8.0 fibrinogen (Lald IIB in 0.2 ~ phosphate buffer), 0.4 ml 
thrombin (50 units/ml). 
Clotting mixture (pH 6.8) : 0.2 ml sample of incubation mixture, 0.02 ml 0.5 ~r Na,HPO, 
with azoprotein or bovine albumin (50 mg/ml). 
Period of thrombin-fibrinogen 
incubation at pH 5.1 
10 
rain. 
5 
15 
3O 
60 
120 
hrs. 
16 
Clotting times of samples  at pH 6.8 
with bovine 
albumin (control) 
190 
155 
150 
120 
105 
95 
48 
with 4-arsonophenyl  azoprot  ein 
(preparation M9) 
5~C. 
150 
100 
65 
45 
40 
32 
10 
All procedures at 23°C. Clotting times measured by technique of Laki (1). 
phenylazoproteins as is shown in Table VI, but 2 non-acidic azoproteins, azo- 
peptones,  and 2  azoamino acids failed to show this  effect, and indeed,  the  2 
azoamino acids caused a slight inhibition. There is thus again identity between 
those azo derivatives which possess an overall anticoagulant activity with those 
which cause acceleration of fibrin polymerization. 
(b) Effects of azoproteins on systems in which fibrin polymerization is inhibited 
by raised electrolyte concentration:  Acidic azoproteins also promote polymeriza- 
tion of fibrin when this is delayed by high electrolyte concentrations, as may be 
seen in Fig. 5.  When 4-sulfonophenylazoproteins and 4-carboxyphenylazopro- 
teins were added to thrombin-fibrinogen mixtures their anticoagulant effective- 
ness  became  progressively less  as  the  salt  concentration  was  increased.  At 
concentrations  from  0.30  ~  KC1  clotting  was  considerably  delayed  in  the J.  D.  BRO0  "M'~- AND  JOHN  G.  KIDD  477 
controls,  but in  these systems the added azoproteins produced a  marked re- 
duction in the dotting times. 
Low Capadty of Acidic Azoproteins to Combine with Fully Polymerized Fibrin.-- 
When  clots  obtained from coagulation mixtures  containing  azoproteins were 
removed and carefully washed in physiological saline virtually no color remained 
with them. The indication that acidic azoproteins were not bound to the fibrin 
clot in substantial amounts was confirmed in a number of other ways. For ex- 
TABLE  VI 
The Effect of Azoprotdns, Azopeptones, and Azoamino Acids on the 
Polymerization of Fibrin 
Clotting mixture (pH 6.8) : 0.02 ml 0.5 M  Na2HPO4, 0.02 ml solutions of test substances in 
0.15 x~ NaC1, pH adjusted to 7.0, 0.2 ml flbrinogen-thrombin mixture pH 5.1, incubated for 
8 hours.* 
Concentration 
Test substance  Preparation  in clotting  C~otting time 
mixture 
Bovine albumin.. 
4-Sulfonophenylazoalbumin. 
4-Carboxyphenylazoalbumin 
$2 
PAB3 
raging 
4.0 
4.0 
4.0 
4-Aminophenylazoalbumin  .... 
Phenylazoalbumin. 
4-Arsonophenylazopeptone  .... 
4-Arsonophenylazohistidine. 
4-Arsonophenylazotyrosine... 
Sulfanilic acid. 
Arsanilic acid. 
~-Aminobenzoic acid. 
--  4.0 
--  4.0 
4.0 
--  4.0 
--  4.0 
--  0.8 
--  0.8 
--  0.8 
SeC, 
50 
10 
10 
43 
50 
52 
85 
80 
51 
51 
51 
* Prepared as described in Table V. Clotting time measured from addition of fibrinogen- 
thrombin to other previously mixed reagents. All procedures at 23°C. 
ample, in one experiment the optical density (at 390 m/z) of a dotting mixture 
containing human plasma (final dilution  1/5)  and 4-arsonophenylazoalbumin 
(preparation M9, 0.6 mg/ml final concentration) was measured before clotting 
had been induced by the addition of strong thrombin preparation, with removal 
of the clot after clotting was complete. A  decrease in optical density of  only 
7.9 per cent resulted.  Plasma itself has a  very low optical density relative to 
azoprotein under the conditions used.  Since the optical density of azoprotein- 
plasma mixtures is higher than the sum of their separate optical densities, (pre- 
sumably due to complex formation with fibrinogen), this figure probably repre- 
sents even too high an estimate of azoprotein binding to the clot. Similar results 
were obtained using purified  fibrinogen  (Pentex Inc.,  final concentration 0.5 478  ARSENIC  AZOPROTEINS.  H 
mg/ml)  and  4-arsonophenylazoprotein  (preparation  M9,  final  concentration 
0.06 mg/ml). Mter clotting the optical density decreased only 5.3 per cent. 
Findings Bearing on the Mechanism of Inhibition of Lymphoma 6C3HED in 
Viw  by  4-Arsonophenylazoprotein.--Experiments  performed  on  many  spoil- 
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FIG. 5. The effect of various concentrations of KCI on the anticoagulant activity of acidic 
azoproteins. Bovine fibrinogen, purified according to Laki (1) was dissolved (300 mg per cent) 
with different amounts of KC1 and azoprotein (AP) to give the concentrations shown. In the 
control, bovine albumin 3 mg/ml was used. Clotting times were measured from the addition 
of 0.1 ml thrombin (10 units/ml)  to 0.3 ml of fibrinogen containing solutions. Temperature 
38°C, pH 7.0. 
taneous and  transplanted  tumors have shown the  greatly varied patterns  of 
sensitivity of different tumors to chemotherapeutic agents,  (see,  for instance 
Sugiura,  reference  15).  Now,  mouse  Lymphoma 6C3HED,  in  contrast  to 
its sensitivity to 4-arsonophenylazoprotein, is resistant  to the effects of most 
agents commonly used in the therapy of human and experimental tumors (16, 
17). However, a number of experiments by Bass and Probert (18)  showed that 
this lymphoma was unusually sensitive to inhibition by colchicine.  Complete J.  D.  BROOME  AND  JOHN  G.  KIDD  479 
regression of established,  palpable  tumors was obtained in a high proportion 
of treated animals (30 to 100 per cent in different groups). It should be noted 
that colchicine is in general of very limited effectiveness in the  treatment of 
experimental  tumors, (see, for instance, Ludford, reference 19, and Eigsti and 
Dustin, reference 20). Of many tumor cell lines tested by different workers only 
one can be considered to have a sensitivity to colchicine even comparable  to 
that of Lymphoma 6C3HED and this, like Lymphoma 6C3HED, originated 
as a thymic lymphoma induced in a  C3H mouse by estrogens (21). Now, the 
actions of colchicine and of arsenic  on cells of many different kinds, appear 
remarkably similar on microscopical examination.  Both agents powerfully in- 
hibit mitosis.  Colchicine, produces arrest of mitosis in metaphase, by destruc- 
tion of the mitotic spindle, as was first shown by Dustin and his co-workers (22). 
Closely similar changes due to arsenic were shown by Piton (23), Dusfin and 
Gr~goire (24), and Ludford (25). 
The purpose of the experiments now to be described was to determine whether 
the  inhibitory action  of  both  4-arsonophenylazoproteins  and  colchicine  on 
Lymphoma  6C3HED could be correlated with similar degrees of activity on the 
mitotic process. 
Actions of 4-Arsonopkenylazoprotein,  Arsanilic Acid, and Colchiclne on Cells 
of Lymphoma 6C3HED and on Their Mitosis.--Preliminary microscopical ex- 
amination of sections  of a  number of 6C3HED  lymphomas treated with 4- 
arsonophenylazoprotein  showed that before necrosis  occurred, mitotic figures 
became particularly numerous (17). These actions of 4-arsonophenylazoprotein 
were investigated in more detail, and compared with those brought about by 
other agents. 
Groups of ZBC mice (19 to 23 gin) were implanted with 500,000 6C3HED 
cells subcutaneously in each  flank.  In  11  days tumors 1.0  to  1.5  cm across 
formed at each implantation site.  Treatment of the  tumor bearing  mice  by 
3  daily intraperitoneal injections  of 4-arsonophenylazoprotein,  colchicine, or 
arsanilic acid in doses indicated in the text, was then begun. Two treated mice 
were sacrificed each day. In these, tumors were removed and carefully separated 
from the abdominal musculature, slices of the tumors were then cut vertically 
through the longest axis, preserving the deep surface. On each day the 4 sepa- 
rate tumor samples obtained were fixed in Zenker's solution or neutral formalin. 
Sections of each tumor were stained with hematoxylin and eosin and by Feul- 
gen's method. The remaining tumor tissue was removed and pressed through 
a  metal mesh into a  quantity of Ringer's solution  containing 20 gm bovine 
albumin (Armour Pharmaceutical Company fraction IV) at pH 7.2, to yield a 
suspension  of free cells which was lightly centrifuged and smear preparations 
made from the sediment. These were air-dried, fixed in absolute methanol and 
stained with May-Grunewald-Giemsa and by Feulgen's method. 
Mitotic counts were performed on tumor tissue sections in their most highly 
vascularized and actively growing parts, that is, in tissue immediately adjacent 480  ARSENIC AZOPROTEINS. II 
to the abdominal musculature. In all cases mitoses became less frequent in the 
center of the tumor. In each tumor the number of mitoses in 2000 cells was 
counted. 
Smear preparations gave mitotic counts considerably lower than were ob- 
tained from the sections, the reason for this lying most probably in the selection 
of cells which occurs in preparing the suspensions, the central cells with a low 
mitotic rate presumably being pressed through the mesh more readily than 
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FIG. 6.  Mitotic counts on 6C3HED tumors in untreated ZBC mice. The figures show the 
maximum and minimum numbers of mitotic forms in 2 tumors in each of 2 mice on the days in- 
dieated. 
Figures showing distribution of different mitotic stages represent average results from tu- 
mor preparations of 2 mice on each of the days indicated. 
the peripheral cells which were enclosed in connective tissue.  However smear 
preparations were most suitable for obtaining counts of the relative proportions 
of mitoses at each stage, due to the great amount of cell detail which could be 
observed in them under the oil-immersion objective. The distribution  of the 
different mitotic stages was in general similar in both sections and smear prepa- 
rations.  The .results  of  these  experiments  are  shown  in  the  accompanying 
Figs. 6 to 9. 
(a) Untreated controls: As shown in Fig. 6, the percentage of cells undergoing 
mitosis remained relatively constant, between 1.4 and 2.1 per cent, in untreated 
controls throughout the test period. The distribution of the  different mitotic 
forms was also constant; metaphase forms were rather more numerous (45  to 
51 per cent) than prophase forms (40 to 45 per cent) while anaphase-telophase 
forms (5 to 15 per cent) were least common. ~. D.  BROOM~ AND  ~OHN  O. KIDD  481 
(b) Colchicine:  Fig. 7 shows that as anticipated colchicine brought about a 
marked increase in the number of mitotic figures in treated tumors. When given 
in a dosage of 0.025 rag/day for 3 days (the maximum quantity tolerated) the 
number of mitoses rose to a maximum of 20.2 per cent by the 4th day from 
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Fzo. 7.  Mitotic counts on 6C3HED tumors in ZBC mice treated with colchicine. Results A 
and B were obtained from separate experiments, counts being performed in each as described 
in Fig. 6. 
beginning treatment; of these 89 per cent were metaphase forms. At this time 
the tumors had decreased markedly in size but on microscopic examination they 
appeared as discrete  white plaques,  which  showed none of the hemorrhagic 
change found by others in less sensitive  tumors treated with colchicine (19). 
The lymphomas showed  considerable  cell damage, many cells were swollen, 
eosinophilic and had lost their normally observable  detailed structure, many 
of the nuclei were pyknotic and others were undergoing  fragmentation. The 482  ARSENIC  AZOP~.OTEIN~.  11" 
microscopic changes and the apparent .absence of vascular damage closely re- 
sembled the findings of Strong eta/. in the treatment of their colchicine-sensi- 
five C3H lymphoma (21).  On the 4th day, however, with cessation of treat- 
ment, the number of mitotic forms was considerably less, cell damage was still 
observable  but  less  prominently.  Subsequently the  appearances  rapidly re- 
turned to control levels. Failure to bring about complete regression was prob- 
ably related to the relatively large size of the tumors and to the short duration 
of treatment, for, in another experiment in which treatment was begun on the 
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FIo. 8.  Mitotic counts on 6C3HED tumors in ZBC mice treated with arsanilic acid. Re- 
suits A  and B were obtained from separate experiments, counts being performed in each as 
described in Fig. 6. Arsunilic acid dissolved in 0.1 N NaOH and pH adjusted to 7.0 was used 
for treatment. 
6th day after implantation, lymphomas were completely supressed in 2 of 3 
mice given 5 daily injections of 0.020 mg colchicine per day, and in 3 of 3 mice 
when a dosage of 0.025 mg was given. No obvious general toxicity was produced 
by these doses. 
(c) Arsanilic acid: Arsanilic acid administered in a dosage of 1.5 mg per day 
(0.5 mg As) produced no significant rise in the number of mitoses in the tumor. 
3.0 rag/day produced marked toxicity in the recipient animals and for this 
reason it was only possible to administer 2 doses. Even at this level of treatment 
the effect on mitosis was slight. The proportion of mitotic figures reached 5.4 
per cent as a maximum and decreased within 48 hours of ending treatment,  to 
the same level as in untreated controls. 
(d) 4-Arsonophenylagoallrumin: The effect of 4-arsonophenylazoalbumin on 
Lymphoma 6C3HED  was considerably different from that produced by other 
agents. In Fig. 9 it will be seen that 24 hours after beginning treatment, the j.  D.  BROOM~. AND JOHN G.  KIDD  483 
azoprotein had produced a  moderate increase  in  the number of mitoses and 
particularly in the  proportion of  metaphase forms.  On succeeding  days the 
number of mitoses increased gradually, reaching 4.2 per cent by the 4th day. 
But, after this time the porportion of cells in mitosis increased strikingly, on the 
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FIG. 9.  Mitotic counts on 6C3HED tumors in ZBC mice treated with 4-arsonophenylazo- 
albumin. Preparation B8, As 1.8 per cent was used. 
The figures showing the numbers of mitotic forms represent results from 2 experiments, 
each employing  2 mice, except for day 5 which represents results from only i animal in each 
experiment. The figures of distribution of different mitotic stages represent results from tumor 
preparations of 2 mice  on each of the days indicated. 
5th day to 10.1 per cent, of which 90 per cent were metaphase forms; on the 6th 
day it reached 21.0 per cent. By this time there was marked cell destruction and 
indeed, while it was possible to examine sections from 4 experimental animals 
on each of the previous days, by the 6th day 2 of the animals showed tumors in 
such advanced necrosis that mitotic counts could not be performed on them. It 484  ARSENIC  AZOPROTEINS.  II 
should be noted that this mitotic crisis and tumor necrosis occurred 3 days after 
treatment ended, in marked contrast to the findings with colchicine and arsanilic 
acid, in which the number of mitoses rapidly decreased after  treatment was 
ended. 
Abnormal mitotic forms were found in all the smear preparations of Lym- 
phoma 6C3HED which were examined, including those from untreated controls, 
but  they  became  considerably  more  numerous  in  animals  treated  with 
colchicine or 4-arsonophenylazoprotein. The changes of  C-mitosis, which are 
associated with spindle damage (26),  were produced by both substances. The 
"ball-metaphase"  with  the appearances of chromosomal adhesion and loss of 
orientation  was  particularly  commonly  seen,  as  were multipolar  mitoses, 
"lagging" chromosomes and anaphase bridging. 
Although colchicine and presumably 4-arsonophenylazoproteins too, inhibit 
cell processes other than mitosis, the close  parallel  observed  microscopically 
between the 2 processes  provides considerable evidence that metaphase arrest 
may in fact be a major cause of tumor cell destruction. Furthermore, daily ex- 
amination of tumor size in similarly treated animals which were not used for 
histological preparations showed that reduction in tumor size follbwed closely 
the periods of maximal mitotic arrest.  There was  no evidence of any other 
reaction produced on the tumors by co!chicine or 4-arsonophenylazoprotein, 
and particularly no evidence of vascular damage to the tumors. In both cases 
the regressing tumors were converted into pale bloodless plaques,  tumors and 
other tissues too, in animals treated with  4-arsonophenylazoprotein acquiring 
its yellow color. 
DISCUSSION 
In  this  and an associated  paper  certain properties exhibited by 4-arsono- 
phenylazoproteins  as  anticoagulants  and  as  antilymphoma agents  are  de- 
scribed, and the possibility is considered that the anticoagulant and  antilym- 
phoma effects may come about through related means. 
As anticoagulants the 4-arsonophenylazoproteins present a number of strik- 
ing features. The experiments now described show that these substances form 
part  of a  larger group of previously unrecognized anticoagulants, the acidic 
azoproteins. Strict structural requirements determine their anticoagulant effec- 
tiveness: the possession of free acidic groups and their attachment through azo 
linkages to protein molecules. When chemically related substances which did 
not possess each of these characteristics were examined they were found to be 
devoid of anticoagulant activity. 
A  number of negatively charged macromolecular substances resemble  the 
acidic azoproteins in being anticoagulants. Dextran sulfate, polyanethol sul- 
fate, and most notably heparin are all members of this class.  It is significant, 
however, that while these and previously reported macromolecular substances 
are dependent for anticoagulant activity on the sulfonic groups they contain, j.  D.  BROOME  AND  JOHN  G.  KIDD  485 
azoproteins  having not only this group but 2 others,  namely carboxylic and 
arsonlc groups, are also highly effective anticoagulants. 
How do the acidic azoproteins  bring about their anticoagulant effect? As is 
the case with other anticoagulants their actions are complex. It has here been 
shown that the final stages of clot formation, namely the conversion of fibrino- 
gen to fibrin, form an important site of the inhibition. A number of other experi- 
ments, which are not reported here since they do not appear relevant to an 
understanding of the antilymphoma activity of some of these substances, show 
that the acidic azoproteins produce additional inhibitory effects on other stages 
of coagulation, particularly on thromboplastin generation. 
Evidence has now been presented to show that acidic azoproteins inhibit the 
clotting of fibrinogen  through formation of a  fibrinogen-azoprotein  complex 
which is resistant to the enzymic action of thrombin. Also that azoproteins 
react with polymerizing fibrin, the reaction leading uniquely to an acceleration 
of this process. Acidic azoproteins are much more reactive with fibrinogen and 
fibrin monomers  than with fully formed fibrin, for after polymerization very 
little azoprotein remains with the clot. 
Earlier workers have shown that fibrinogen can form complexes with several 
macromolecular  substances  which carry a strong negative charge.  Such com- 
plexes are formed with polyanethol sulfate and under some conditions  with 
heparin and other carbohydrate polysulfruic  acid esters  (27-29).  No effect of 
these or similar substances  on the fibrin polymerization reactions has however 
been reported.  It is notable that while many substances inhibit the polymeriza- 
tion reactions (30), acidic azoproteins are the first substances to be clearly shown 
to accelerate these stages. 
The accelerating effect of acidic azoproteins  on fibrin polymerization can be 
explained by reaction between the acidic groups of the azoprotein  and the free 
basic groups  (31) of fibrin subunits. If each molecule of azoprotein complexes 
with several molecules of unpolymerized  or partially polymerized fibrin, these 
would be brought into close proximity and might then more rapidly undergo 
further polymerization.  When polymerization is complete it appears  that few 
sites remain in the fibrin at which combination with azoprotein  can occur, for 
only very small amounts of azoprotein are found in the final clot. 
4-Arsonophenylazoproteins  strongly  inhibit  the  growth  of  Lymphoma 
6C3HED in vivo while other related arsenic-containing  substances  which lack 
anticoagulant activity produce no antilymphoma effects. Lymphoma 6C3HED 
is insensitive to most substances ordinarily used in the treatment of human and 
animal tumors, but it is highly sensitive to colchicine (16--18). Both 4-arsono- 
phenylazoproteins  and  colchicine  cause  a  powerful  metaphase  arrest  in 
6C3HED cells in vivo, as has now been shown, and in a wide variety of different 
cell types arsenicals and colchicine are known to produce this effect by inhibit- 
ing contraction of the mitotic spindle (22-25). 
Inou~, in work on the mitotic apparatus of various animal and plant cells in 486  ARSENIC  AZOPROTEINS.  II 
vivo, has shown the transformation  of the spindle  in metaphase from a  sol in 
which  the molecules  occupy a  random arrangement  to a  fibrous structure in 
which they are arranged  in a  precise longitudinal  pattern  (32).  Mazia,  who 
isolated the mitotic apparatus of sea urchin eggs, has shown that polymeriza- 
tion of the spindle protein is greatly dependent on the balance of --S--S-- and 
--SH groups (33). While undoubtedly bonds of various other kinds are formed, 
hydrogen bonds between --SH groups of adjacent molecules  are particularly 
important,  these being in equilibrium witha relatively small number of inter- 
molecular --S--S-- linkages (34). Trivalent arsenic, in combination with --SH 
groups clearly might inhibit polymerization of the spindle  protein. 
Do the structural characters of 4-arsonophenylazoprotein that determine its 
ability to form complexes with fibrinogen  and fibrin monomers also determine 
its ability to arrest mitosis in proliferating  Lymphoma 6C3HED  cells? The 
studies of Heilbrunn  and  other workers  (see  Heilbrunn,  reference  35)  have 
demonstrated many striking similarities  between processes occuring  in blood 
coagulation and those involved in the formation and contraction of the mitotic 
spindle.  These similarities  have again been reviewed by jensen (36). From the 
present findings, however, it is clear that the anticoagulant effect of 4-arsono- 
phenylazoprotein is not in itself responsible for lymphoma inhibition; for acidic 
azoproteins other than those containing arsenic are strong anticoagulants, yet 
these fail to inhibit tumor growth significantly,  and they fail also to arrest the 
process of mitosis in proliferating Lymphoma 6C3HED cells in viva, as micro- 
scopic studies have shown.  The essential part played by arsenic in conferring 
antilymphoma  properties  on  the  azoproteins  with  which  it  is  combined  is 
further shown by the ability of dimercaprol to interfere with the antilymphoma 
effects of 4-arsonophenylazoprotein. 
From the evidence now presented,  the anticoagulant and tumor inhibitory 
effects of 4-arsonophenylazoproteins may be related in the following way. Since 
4-arsonophenylazoproteins can combine particularly strongly and with consider- 
able specificity with fibrinogen  and polymerizing fibrin,  it may be postulated 
that in cells of Lymphoma 6C3HED the azoprotein combines in a similar  way 
with unpolymerized and polymerizing proteins of the mitotic spindle.  Further- 
more, it should be noted that, under such circumstances,  a high concentration 
of arsenic might be brought to sites dependent for functional activity on their 
sulfhydryl groups. 
But can a molecule  the size of 4-arsonophenylazoprotein enter tumor cells? 
McMaster and Kruse have elegantly demonstrated  the ability of azoproteins 
not only to enter macrophages but also to persist there for long periods (37). 
Like  macrophages,  cells  of  Lymphoma  6C3HED  are  actively  phagocytic, 
ingesting  erythrocytes,  nucleated  cells  and  various  cell  particles  (38,  39). 
Furthermore 6C3HED cells have been shown to accumulate C1Mabeled serum 
albumin in vivo (40);  and it ~as recently been shown that injected 4-arsono- J.  D,  BROOME  AND  JOHN  G.  KIDD  487 
phenylazoproteins are taken up by tumors of a transplantable mouse ependy- 
morea in vivo, though in this case in a  smaller  amount than by the liver or 
other organs  (4l). 
Can reduction of pentavalent  arsenic in 4-arsonophenylazoalbumin  to the 
trivalent form take place in vivo, thus enabling reaction of arsenic with --SH 
groups to occur? Again this seems probable. Voegtlin and Smith have shown 
that  pentavalent  arsenicals  undergo  reduction  in  vivo  before exerting  their 
trypanocidal effects (42). It has also been shown that such activation can occur 
even by incubation of pentavalent arsenicals  with blood in vitro (43). 
Would 4-arsonophenylazoproteins be likely to form complexes with protein 
of the mitotic spindle? Fibrinogen and other natural fibrous proteins have many 
structural features in common, as has been brilliantly shown by Astbury and 
others (see for instance,  reference 44).  Fibrinogen has a  molecular weight of 
approximately 330,000, and like other members of this group is a highly asym- 
metrical molecule (4). Much less information is available about proteins con- 
stituting  the mitotic spindle.  Kane and  Hersh using extracts  of the soluble 
proteins from sea urchin eggs showed these to contain considerable amounts 
of a protein which gelled in the presence of calcium and which was both highly 
asymmetrical and of similar  molecular weight to fibrinogen.  After fertilization 
and  corresponding  with  spindle  formation  the  protein  greatly  decreased in 
amount  (45).  Although this protein, perhaps a  spindle  precursor, is immuno- 
logically different from proteins extracted directly from the mitotic apparatus 
(46), Mazia (47) and Zimmerman (48) have shown that the mitotic apparatus 
consists predominately of a single protein that is solubilized by --SH reagents 
and has a  molecular weight virtually identical  with that  obtained by Kane 
and Hersh. 
From the findings as a whole it can be seen that the hypothesis here presented 
is consistent with what has been learnt thus far about the processes of clotting 
and mitosis, and consistent too with the observations made thus far on the anti- 
coagulant and antilymphoma effects of 4-arsonophenylazoprotein. 
SU'M'~AR¥ 
Experiments here given show that 4-arsonophenylazoproteins form complexes 
with fibrinogen which are resistant to the enzymic action of thrombin, coagula- 
tion being thus inhibited; also that arsenic dzoproteins combine strongly with 
polymerizing fibrin, the reaction leading uniquely to acceleration of the process. 
Ordinary arsenicals  have little or no effect on the proliferation of Lymphoma 
6C3HED  cells in  vivo. 4-Arsonophenylazoproteins,  by contrast,  are strongly 
inhibitory, and they arrest the process of mitosis in metaphase, as does colchi- 
cine. 
Considered together with the observations of the preceding paper, the findings 
suggest  that  4-arsonophenylazoproteins  may  exert  their  anticoagulant  and 488  ARSENIC  AZOPROTEINS.  II 
anfilymphoma effects by similar or related means: in the former instance, by 
combining in vitro with fibrinogen and polymerizing fibrin, thus altering the 
clotting process as mentioned above; and in the latter instance by combining, 
perhaps in a similar way, with polymerizing proteins in the mitotic spindle of 
proliferating Lymphoma 6C3HED  cells,  thus arresting mitosis. 
Further implications of the findings are discussed. 
BIBLIOGRAPHY 
1.  Laki, K., The polymerization of proteins: the action of thrombin on fibrinogen, 
Arch.  Biochem. and Biophysics,  1951, 32, 317. 
2.  Reiner,  J. M., Behavior of Enzyme Systems,  Minneapolis,  Burgess  Publishing 
Co., 1959. 
3.  Lytfleton, J. W., The antithrombin activity of heparin,  Biochem. J.,  1954, 58, 
15. 
4.  Scheraga, I-I. A., and Laskowski, M., The fibrinogen-fibrin conversion, Advances 
Protein Chem., 1957, 12,  1. 
5.  B15mback, B.,  Studies on fibrinogen: its purification  and conversion into fibrin, 
Acta. Physiol. Scand., 1958, 43, (suppl. 148), 7. 
6.  Sherry, S., and Troll, W., The action of thrombin on synthetic substrates,  J. Biol. 
Chem.,  1954, 208,  95. 
7.  Horowitz, F., Schwerin, P., and Tunc, S., The mutual precipitation of proteins 
and azoproteins,  Arch. Biochem., 1947, 11, 515. 
8.  Seegers, W. H., Nieff, M. L., and Vanderbllt,  J. M., Decomposition products of 
fibrinogen and fibrin, Arch. Biochem., 1945, 7, 15. 
9.  McGeathin, R.  L.,  and  Ashley,  B.  D.,  Some azoproteins  and  their isoelectric 
points, Y. Am. Chem. Soc., 1951, 73, 1366. 
10.  Alberty, R. A., A study of the variation of the average isoelectric points of several 
• plasma  proteins with ionic strength, Y. Physic.  and  Colloid Chem., 1949, 53, 
114. 
11. Waugh, D. F., and Livingstone, B. J., Clotting  time and reaction velocity in the 
interaction of bovine fibrinogen and thrombin, Science, 1951, 113, 121. 
12. Waugh, D. F., and Livingstone, B. J., Kinetics of the interaction of bovine fibrino- 
gen and thrombin, J. Physic. and Colloid Chem., 1951, 55, 1206. 
13. Waugh, D. F., and Patch, M. J., The effects of ionic strength on the interaction 
of bovine fibrinogen and thrombin, J. Physic. Chem., 1953, 57, 377. 
14.  Khodorova, E. L., The action of thrombin, Ukrain. Biokhim. Zhur., 1951, 23,439. 
15.  Sugiura,  K., Studies  on a spectrum of mouse and rat tumors, Cancer Research, 
1955, (suppl. 3), 18. 
16.  Bass, A. D., The response of normal and malignant lymphoid  tissue to methyl- 
bis (/3-chloroethyl) amine and ethyl carbamate (urethane)  in adrenaleetomized 
and non-adrenalectomized  mice, Cancer Research, 1948, 8, 503. 
17.  Kidd, J.  G., Effects of arsenic azoproteins  on mouse lymphoma cells in vivo, J. 
Exp. Med.,  1958, 108, 665. 
18.  Bass,  A. D.,  and Probert, C.,  Response  of a  transplantable lymphosarcoma  to 
colchicine, Cancer Research, 1950, 10, 420. J.  D. BR00ME  AND  JOHN  G. KIDD  489 
19. Ludford, R.,  Colchicine in  the  experimental  chemotherapy of cancer,  J.  Nat. 
Cancer Inst.,  1945, 6, 89. 
20.  Eigsti,  O. J., and Dustin, P., Colchicine, Ames, Iowa State College Press,  1955. 
21. Lits, F., Kirschbaum, A., and Strong, L. C., Action of colchicine on a transplanted 
malignant lymphoid neoplasm in mice of the C3H strain, Am. J. Cancer, 1935, 
36, 196. 
22.  Dnstin,  P.,  L'activit6 du laboratoire d'anatomie pathologique de la facultA de 
m6decine  de l'Universit6  libre de Bruxelles,  sous  la  direction  du  professeur 
Albert-Pierre Dustin de 1929 ~ 1939, Arch. Mat. Belg.,  1946, 1, 157. 
23.  Piton, R., Recherches sur les actions  caryodasiques et caryocin6tiques  des com- 
pos6s arsenicaux, Arch. Int. Med., 1929, 5, 355. 
24. Dnstin, A. P., and Gr6goire, C.,  Contribution ~ l'etude de Faction des  poisons 
caryoclasiques  sur les tumeurs animales;  action du cacodylate de Na et de la 
trypaitavine sur le sarcome greff6, type Crocker, de la souris, Bull. Acad. roy. 
reed. Belgiatue, 1933, Lq, 585. 
25.  Ludford, R. J., Action of toxic substances upon division of normal and malignant 
cells in vitro and vivo, Arch. Zellforsch,  1936, 18, 411. 
26.  Levan, A., Colchicine-induced C-mitosis in two mouse ascites tumors, Hereditas, 
1954, 40, 1. 
27.  Stuber,  B.,  and  Lang,  K.  Untersuchunger  zur  Lehre vonder  Blutgerinnung. 
XXIV.  Mitteilung:  Uber  die  Hemmung der  Blutgerinnung  durch  Liquoid, 
Biochem.  Z.,  1932, 244, 214. 
28.  Thomas, L., Smith,  R. T., and Von Korff, R., Cold-precipitation  by heparin of a 
protein in rabbit and human plasma, Proc. Soc. Exp. Biol. and Meal., 1954, 86, 
813. 
29.  Astrup,  T.,  and  Piper,  J.,  Interaction between  fibrinogen  and  polysaccharide 
polysulfuric  acids, Acta. Physiol. Scand.,  1946, 11, 211. 
30.  Shulman,  S., The effects of certain ions and neutral molecules on the conversion 
of fibrinogen to fibrin, Discussions  Faraday Soc.,  1953, 13, 109. 
31.  Caspary~ E. A., Studies on the acetylation of human fibrinogen, Biochem. J., 1956, 
62,507. 
32.  Inou~, S., Polarization optical studies of the mitotic spindle. I. Demonstration of 
spindle fibres in living cells, Chromosoma, 1953, 5,487. 
33.  Mazia, D.,  SH and Growth,  in Glutathione,  (S. Colowick et aI.,  editors)  New 
York, Academic Press,  Inc.,  1954, 209. 
34.  Mazia,  D., Mitchison,  J. M., Medina,  H., and Harris, P., The direct isolation of 
the mitotic apparatus, J. Biophysic. and Biochem.  Cytol, 1961, 10, 467. 
35.  Heilbrunn, L. V.,  The Dynamics of Living Protoplasm,  New York  Academic 
Press,  Inc.,  1956. 
36. Jensen,  E. V., Sulfhydryl-disulfide interchange,  Science,  1959, 130, 1319. 
37. McMaster, P. D., and K_ruse, H., The persistence in mice of certain foreign pro- 
teins and azoprotein tracer-antigens  derived from them, J. Exp. Med.,  1951 
94, 323. 
38.  Stoerk,  H. C., Desoxypyridoxine  observations  in "acute pyridoxine deficiency," 
Ann. New York Acad. Sc., 1950, 52, 1302; Sobin, L. H., Cytoplasmic  inclusions 490  ARSENIC  AZOPROTEINS.  II 
C~  0"] 
of  Lymphosarcoma 6C3HED:  Morphologic  and  Cytochemical  observations, 
Exp. Cell Research, 1961, 24, 189. 
39.  Broome, J. D., unpublished  observations. 
40.  Henderson,  J.  F., and Lepage,  G. A.,  Utilization  of host protein by 6C3HED 
ascites lymphosarcoma in C3H and Swiss mice, Cancer Research~ 1959, 19, 749. 
41.  Mego, J. L., and McQueen, J. D., The uptake of As 74-labeled arsonoazoprotein 
in tissues of tumor-bearing  mice, Cancer Research,  1963, 23, 523. 
42.  Voegtlin, C., and Smith,  H. W.,  Quantitative studies  in chemotherapy.  II. The 
trypanocidal action of arsenic  compounds,  J.  Pharmacol. and Exp.  Therapy 
1920, 15, 475. 
43.  Terry, B. T., Different amounts of transformed atoxyl produced by incubating  1 
per cent and 10 per cent, atoxyl in blood, J. Exp. Med., 1915, 21,258. 
44.  Astbury, W. T., On the structure of biological fibres and the problem of muscle, 
Proc. Roy. Soc. London, Series B, 1945, 134, 303 (Croonian Lecture). 
45.  Kane, R. E., and Hersh, R. T., The isolation and preliminary characterization of 
a major soluble protein of the sea urchin egg, Exp. Cell. Research., 1959, 16, 59. 
46.  Went, H. A., Studies on the mitotic apparatus of the sea urchin by means of anti- 
gen-antibody reactions in agar, J. Biophysic. and Biochem. Cytol., 1959, 6, 447. 
47.  Mazia, D., The organization  of the mitotic apparatus, Fibrous Proteins, 1955, 9, 
335. 
48.  Zimmerman,  A. M., Physico-chemical analysis of the isolated  mitotic apparatus, 
Exp. Cell. Research., 1960, 20, 529. 